Literature DB >> 9738504

DNA hypomethylation leads to elevated mutation rates.

R Z Chen1, U Pettersson, C Beard, L Jackson-Grusby, R Jaenisch.   

Abstract

Genome-wide demethylation has been suggested to be a step in carcinogenesis. Evidence for this notion comes from the frequently observed global DNA hypomethylation in tumour cells, and from a recent study suggesting that defects in DNA methylation might contribute to the genomic instability of some colorectal tumour cell lines. DNA hypomethylation has also been associated with abnormal chromosomal structures, as observed in cells from patients with ICF (Immunodeficiency, Centromeric instability and Facial abnormalities) syndrome and in cells treated with the demethylating agent 5-azadeoxycytidine. Here we report that murine embryonic stem cells nullizygous for the major DNA methyltransferase (Dnmt1) gene exhibited significantly elevated mutation rates at both the endogenous hypoxanthine phosphoribosyltransferase (Hprt) gene and an integrated viral thymidine kinase (tk) transgene. Gene deletions were the predominant mutations at both loci. The major cause of the observed tk deletions was either mitotic recombination or chromosomal loss accompanied by duplication of the remaining chromosome. Our results imply an important role for mammalian DNA methylation in maintaining genome stability.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738504     DOI: 10.1038/25779

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  240 in total

1.  Analysis of human peripheral blood T cells and single-cell-derived T cell clones uncovers extensive clonal CpG island methylation heterogeneity throughout the genome.

Authors:  X Zhu; C Deng; R Kuick; R Yung; B Lamb; J V Neel; B Richardson; S Hanash
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1.

Authors:  A Bellacosa; L Cicchillitti; F Schepis; A Riccio; A T Yeung; Y Matsumoto; E A Golemis; M Genuardi; G Neri
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome.

Authors:  C A Hobbs; S L Sherman; P Yi; S E Hopkins; C P Torfs; R J Hine; M Pogribna; R Rozen; S J James
Journal:  Am J Hum Genet       Date:  2000-08-07       Impact factor: 11.025

Review 4.  DNA methylation changes in gastrointestinal disease.

Authors:  Minoru Toyota; Fumio Itoh; Takefumi Kikuchi; Ayumi Satoh; Toshiro Obata; Hiromu Suzuki; Suguru Ishii; Takao Endo; Takashi Tokino; Kohzoh Imai
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

5.  CpG methylation modifies the genetic stability of cloned repeat sequences.

Authors:  Kerrie Nichol; Christopher E Pearson
Journal:  Genome Res       Date:  2002-08       Impact factor: 9.043

Review 6.  Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research.

Authors:  Akiko Hayashi-Takagi; Marquis P Vawter; Kazuya Iwamoto
Journal:  Biol Psychiatry       Date:  2013-10-18       Impact factor: 13.382

7.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Type 2 NF1 deletions are highly unusual by virtue of the absence of nonallelic homologous recombination hotspots and an apparent preference for female mitotic recombination.

Authors:  Katharina Steinmann; David N Cooper; Lan Kluwe; Nadia A Chuzhanova; Cornelia Senger; Eduard Serra; Conxi Lazaro; Montserrat Gilaberte; Katharina Wimmer; Viktor-Felix Mautner; Hildegard Kehrer-Sawatzki
Journal:  Am J Hum Genet       Date:  2007-10-31       Impact factor: 11.025

Review 9.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

10.  MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells.

Authors:  Enders K O Ng; Rufina Li; Vivian Y Shin; Jennifer M Siu; Edmond S K Ma; Ava Kwong
Journal:  Tumour Biol       Date:  2013-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.